What is the tissue transglutaminase antibody (TG‑Ab) laboratory test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is a TG-Ab (Tissue Transglutaminase Antibody) Lab Test?

The tissue transglutaminase antibody (TG-Ab or TG2-IgA) test is a blood test that measures IgA antibodies against tissue transglutaminase enzyme, serving as the primary serological screening tool for celiac disease. 1

Primary Clinical Purpose

  • TG2-IgA is the crucial first-line serology test for detecting and diagnosing celiac disease in both adults and children 1
  • The test identifies autoantibodies produced when individuals with celiac disease consume gluten, as tissue transglutaminase is the main autoantigen recognized in this condition 2
  • Sensitivity ranges from 87.5-100% and specificity from 94-98% for detecting untreated celiac disease 3, 4, 5

Diagnostic Thresholds and Interpretation

High-level positivity (>10 times the upper normal limit) is highly reliable for diagnosing active celiac disease:

  • When TG2-IgA exceeds 10x the upper limit of normal (ULN), combined with positive endomysial antibody in a second sample, the positive predictive value approaches virtually 100% 1
  • At ≥10x ULN threshold, TG2-IgA demonstrates 99.3% specificity and 91.4% positive predictive value 5
  • Recent evidence suggests TG2-IgA at ≥10x ULN actually exceeds endomysial antibody testing in specificity 5
  • There is a consistent correlation between antibody levels and histological severity of mucosal damage (Marsh grading), with higher antibody levels corresponding to more severe intestinal damage 6

Critical Testing Considerations

Total IgA levels must be checked concurrently, as IgA deficiency causes false-negative results:

  • IgA deficiency is an infrequent but important cause of false-negative TG2-IgA testing despite active celiac disease 1
  • In IgA-deficient patients, both TG2-IgA and endomysial antibody tests will be negative even with biopsy-proven celiac disease 7
  • When IgA deficiency is present, IgG-based testing (TG2-IgG and deamidated gliadin antibody) should be performed instead 1
  • IgG isotype testing for TG2 antibody is NOT specific in the absence of IgA deficiency and should not be used routinely 1

Common Pitfalls and Discordant Results

Positive TG2-IgA with negative endomysial antibody results require cautious interpretation:

  • This discordance pattern has low probability of true celiac disease (only 17.7% confirmed in one study) 8
  • Significant variability exists among different commercial TG2-IgA assay methods, with overall agreement ranging only 28.5-77.7% 8
  • Patients positive on multiple different TG2-IgA assays are more likely to have true celiac disease (29.5%) compared to those positive on only one method (2.5%) 8
  • False-positive results can occur, particularly in patients with type 1 diabetes mellitus 5
  • Discordant results warrant referral to a celiac disease reference center for prolonged follow-up 8

Role in Diagnostic Algorithm

  • In patients with strongly positive serology but negative biopsies, TG2-IgA should still be performed, and repeat biopsies may be considered 1
  • When celiac disease is first identified by intestinal biopsies, celiac-specific serology should be obtained as confirmatory testing before starting a gluten-free diet 1
  • The test can be used for monitoring, though antibody levels may persist or fluctuate during treatment 4, 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.